1 |
Sonveaux, P., Copetti, T., De Saedeleer, C. J., Vegran, F., Verrax, J., Kennedy, K. M., Moon, E. J., Dhup, S., Danhier, P., Frerart, F., Gallez, B., Ribeiro, A., Michiels, C., Dewhirst, M. W. and Feron, O. (2012) Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis. PloS One 7, e33418.
DOI
|
2 |
Sonveaux, P., Vegran, F., Schroeder, T., Wergin, M. C., Verrax, J., Rabbani, Z. N., De Saedeleer, C. J., Kennedy, K. M., Diepart, C., Jordan, B. F., Kelley, M. J., Gallez, B., Wahl, M. L., Feron, O. and Dewhirst, M. W. (2008) Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J. Clin. Invest. 118, 3930-3942.
|
3 |
Sooparb, S., Price, S. R., Shaoguang, J. and Franch, H. A. (2004) Suppression of chaperone-mediated autophagy in the renal cortex during acute diabetes mellitus. Kidney Int. 65, 2135-2144.
DOI
|
4 |
Spear, B. B., Heath-Chiozzi, M. and Huff, J. (2001) Clinical application of pharmacogenetics. Trends Mol. Med. 7, 201-204.
DOI
|
5 |
Stegmeier, F., Warmuth, M., Sellers, W. R. and Dorsch, M. (2010) Targeted cancer therapies in the twenty-first century: lessons from imatinib. Clin. Pharmacol. Ther. 87, 543-552.
DOI
|
6 |
Strausberg, R. L., Simpson, A. J., Old, L. J. and Riggins, G. J. (2004) Oncogenomics and the development of new cancer therapies. Nature 429, 469-474.
DOI
|
7 |
Takeuchi, H., Kondo, Y., Fujiwara, K., Kanzawa, T., Aoki, H., Mills, G. B. and Kondo, S. (2005) Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Cancer Res. 65, 3336-3346.
|
8 |
Vander Heiden, M. G. (2011) Targeting cancer metabolism: a therapeutic window opens. Nature reviews. Nat. Rev. Drug Discov. 10, 671-684.
DOI
ScienceOn
|
9 |
Venter, J. C., Adams, M. D., Myers, E. W., Li, P. W., Mural, R. J. and Sutton, G. G., et al. (2001) The sequence of the human genome. Science 291, 1304-1351.
DOI
ScienceOn
|
10 |
Ward, P. S. and Thompson, C. B. (2012) Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 21, 297-308.
DOI
ScienceOn
|
11 |
Wilhelm, S. M., Adnane, L., Newell, P., Villanueva, A., Llovet, J. M. and Lynch, M. (2008) Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther. 7, 3129-3140.
DOI
|
12 |
Yun, M., Bang, S. H., Kim, J. W., Park, J. Y., Kim, K. S. and Lee, J. D. (2009) The importance of acetyl coenzyme A synthetase for 11Cacetate uptake and cell survival in hepatocellular carcinoma. J. Nucl. Med. 50, 1222-1228.
DOI
|
13 |
Zakikhani, M., Dowling, R., Fantus, I. G., Sonenberg, N. and Pollak, M. (2006) Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 66, 10269-10273.
DOI
|
14 |
Zhao, Y., Liu, H., Riker, A. I., Fodstad, O., Ledoux, S. P., Wilson, G. L. and Tan, M. (2011) Emerging metabolic targets in cancer therapy. Front. Biosci. 16, 1844-1860.
DOI
|
15 |
Bernards, R. (2012) A missing link in genotype-directed cancer therapy. Cell 151, 465-468.
DOI
|
16 |
Arduino, L. J. and Mellinger, G. T. (1967) Clinical trial of busulfan (NSC-750) in advanced carcinoma of prostate. Cancer Chemother. Rep. 51, 295-303.
|
17 |
Armour, A. A. and Watkins, C. L. (2010) The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer. Eur. Respir. Rev. 19, 186-196.
DOI
|
18 |
Ben Sahra, I., Laurent, K., Loubat, A., Giorgetti-Peraldi, S., Colosetti, P., Auberger, P., Tanti, J. F., Le Marchand-Brustel, Y. and Bost, F. (2008) The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27, 3576-3586.
DOI
ScienceOn
|
19 |
Birsoy, K., Wang, T., Possemato, R., Yilmaz, O. H., Koch, C. E., Chen, W. W., Hutchins, A. W., Gultekin, Y., Peterson, T. R., Carette, J. E., Brummelkamp, T. R., Clish, C. B. and Sabatini, D. M. (2013) MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors. Nat. Genet. 45, 104-108.
|
20 |
Brook, J., Bateman, J. R. and Steinfeld, J. L. (1964) Evaluation of Melphalan (Nsc-8806) in Treatment of Multiple Myeloma. Cancer Chemother. Rep. 36, 25-34.
|
21 |
Buck, E., Eyzaguirre, A., Haley, J. D., Gibson, N. W., Cagnoni, P. and Iwata, K. K. (2006) Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity. Mol. Cancer Ther. 5, 2051-2059.
DOI
|
22 |
Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70.
DOI
ScienceOn
|
23 |
DeBerardinis, R. J., Mancuso, A., Daikhin, E., Nissim, I., Yudkoff, M., Wehrli, S. and Thompson, C. B. (2007) Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc. Natl. Acad. Sci. U.S.A. 104, 19345-19350.
DOI
|
24 |
Chabner, B. A. and Roberts, T. G., Jr. (2005) Timeline: Chemotherapy and the war on cancer. Nat. Rev. Cancer 5, 65-72.
DOI
|
25 |
Chan, S. (2004) Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br. J. Cancer 91, 1420-1424.
DOI
|
26 |
Cheong, H., Lu, C., Lindsten, T. and Thompson, C. B. (2012) Therapeutic targets in cancer cell metabolism and autophagy. Nat. Biotechnol. 30, 671-678.
DOI
|
27 |
Edmonson, J. H., Lagakos, S., Stolbach, L., Perlia, C. P., Bennett, J. M., Mansour, E. G., Horton, J., Regelson, W., Cummings, F. J., Israel, L., Brodsky, I., Shnider, B. I., Creech, R. and Carbone, P. P. (1976) Mechlorethamine (NSC-762) plus CCNU (NSC-79037) in the treatment of inoperable squamous and large cell carcinoma of the lung. Cancer Treat. Rep. 60, 625-627.
|
28 |
Ertmer, A., Huber, V., Gilch, S., Yoshimori, T., Erfle, V., Duyster, J., Elsasser, H. P. and Schatzl, H. M. (2007) The anticancer drug imatinib induces cellular autophagy. Leukemia 21, 936-942.
|
29 |
Evans, J. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R. and Morris, A. D. (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330, 1304-1305.
DOI
|
30 |
Fan, J., Ye, J., Kamphorst, J. J., Shlomi, T., Thompson, C. B. and Rabinowitz, J. D. (2014) Quantitative flux analysis reveals folatedependent NADPH production. Nature 510, 298-302.
DOI
|
31 |
Gilman, A. (1963) The initial clinical trial of nitrogen mustard. Am. J. Surg. 105, 574-578.
DOI
|
32 |
Fausel, C. (2007) Targeted chronic myeloid leukemia therapy: Seeking a cure. Am. J. Health Syst. Pharm. 64, S9-15.
|
33 |
Fisher, B. K. and Elliott, G. B. (1965) Triple drug therapy with actinomycin D (Nsc-3053), chlorambucil (Nsc-3088), and methotrexate (Nsc-740) in metastatic solid tumors in children. Cancer Chemother. Rep. 45, 45-51.
|
34 |
Foley, J. F. and Kennedy, B. J. (1964) Effect of cyclophosphamide (Nsc-26271) on far-advanced neoplasia. Cancer Chemother. Rep. 34, 55-58.
|
35 |
Goldman, J. M. and Melo, J. V. (2003) Chronic myeloid leukemia-- advances in biology and new approaches to treatment. N. Engl. J. Med. 349, 1451-1464.
DOI
|
36 |
Gorzalczany, Y., Gilad, Y., Amihai, D., Hammel, I., Sagi-Eisenberg, R. and Merimsky, O. (2011) Combining an EGFR directed tyrosine kinase inhibitor with autophagy-inducing drugs: a beneficial strategy to combat non-small cell lung cancer. Cancer Lett. 310, 207-215.
DOI
|
37 |
Haugrud, A. B., Zhuang, Y., Coppock, J. D. and Miskimins, W. K. (2014) Dichloroacetate enhances apoptotic cell death via oxidative damage and attenuates lactate production in metformin-treated breast cancer cells. Breast Cancer Res. Treat. 147, 539-550.
DOI
|
38 |
Hay, N. and Sonenberg, N. (2004) Upstream and downstream of mTOR. Genes Dev. 18, 1926-1945.
DOI
|
39 |
Jackson, R. C. (1987) Unresolved issues in the biochemical pharmacology of antifolates. NCI Monogr. 9-15.
|
40 |
Jacobs, E. M., Peters, F. C., Luce, J. K., Zippin, C. and Wood, D. A. (1968) Mechlorethamine HCl and cyclophosphamide in the treatment of Hodgkin's disease and the lymphomas. JAMA 203, 392-398.
DOI
|
41 |
Janku, F., McConkey, D. J., Hong, D. S. and Kurzrock, R. (2011) Autophagy as a target for anticancer therapy. Nat. Rev. Clin. Oncol. 8, 528-539.
DOI
|
42 |
Jiralerspong, S., Palla, S. L., Giordano, S. H., Meric-Bernstam, F., Liedtke, C., Barnett, C. M., Hsu, L., Hung, M. C., Hortobagyi, G. N. and Gonzalez-Angulo, A. M. (2009) Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J. Clin. Oncol. 27, 3297-3302.
DOI
|
43 |
Kanzawa, T., Germano, I. M., Komata, T., Ito, H., Kondo, Y. and Kondo, S. (2004) Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ. 11, 448-457.
DOI
|
44 |
Kimura, T., Takabatake, Y., Takahashi, A. and Isaka, Y. (2013) Chloroquine in cancer therapy: a double-edged sword of autophagy. Cancer Res. 73, 3-7.
|
45 |
Klionsky, D. J., Abdalla, F. C., Abeliovich, H., Abraham, R. T., Acevedo- Arozena, A. and Adeli, K., et al. (2012) Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 8, 445-544.
DOI
|
46 |
Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C. and Baldwin, J., et al. (2001) Initial sequencing and analysis of the human genome. Nature 409, 860-921.
DOI
|
47 |
Lottmann, H. B., Margaryan, M., Bernuy, M., Rouffet, M. J., Bau, M. O., El-Ghoneimi, A., Aigrain, Y., Stenberg, A. and Lackgren, G. (2002) The effect of endoscopic injections of dextranomer based implants on continence and bladder capacity: a prospective study of 31 patients. J. Urol. 168, 1863-1867.
DOI
|
48 |
Regelson, W., Holland, J. F., Frei, E., 3rd, Gold, G. L., Hall, T., Krant, M. and Miller, S. O. (1964) Comparative clinical toxicity of 6-mercaptopurine (Nsc-755)-1 and 6-mercaptopurine ribonucleoside (Nsc-4911)-2 administered intravenously to patients with advanced cancer. Cancer Chemother. Rep. 36, 41-48.
|
49 |
Michelakis, E. D., Webster, L. and Mackey, J. R. (2008) Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br. J. Cancer 99, 989-994.
DOI
|
50 |
Nieman, K. M., Kenny, H. A., Penicka, C. V., Ladanyi, A., Buell-Gutbrod, R., Zillhardt, M. R., Romero, I. L., Carey, M. S., Mills, G. B., Hotamisligil, G. S., Yamada, S. D., Peter, M. E., Gwin, K. and Lengyel, E. (2011) Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat. Med. 17, 1498-1503.
DOI
|
51 |
Robinson, M. M., McBryant, S. J., Tsukamoto, T., Rojas, C., Ferraris, D. V., Hamilton, S. K., Hansen, J. C. and Curthoys, N. P. (2007) Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES). Biochem. J. 406, 407-414.
DOI
|
52 |
Sausville, E. A. and Johnson, J. I. (2000) Molecules for the millennium: how will they look? New drug discovery year 2000. Br. J. Cancer 83, 1401-1404.
DOI
|
53 |
Seltzer, M. J., Bennett, B. D., Joshi, A. D., Gao, P., Thomas, A. G., Ferraris, D. V., Tsukamoto, T., Rojas, C. J., Slusher, B. S., Rabinowitz, J. D., Dang, C. V. and Riggins, G. J. (2010) Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res. 70, 8981-8987.
DOI
|